This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response
BMC Cancer Open Access 26 March 2022
-
Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators
Leukemia Open Access 25 July 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999–1003.
Ho-Wan IP, Chi-Chiu SO . Deep molecular response in chronic myelogenous leukemia: ensuring accuracy and consistency. Leukemia 2015; 29: 1620–1621.
Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S et al. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. J Clin Pathol 2016; e-pub ahead of print 2 February 2016 doi:10.1136/jclinpath-2015-203538.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author holds equity in Monoquant Pty Ltd, which holds a patent related to sequencing of BCR-ABL1.
Rights and permissions
About this article
Cite this article
Morley, A. Reporting results for deep molecular responses in chronic myeloid leukemia. Leukemia 30, 1630–1631 (2016). https://doi.org/10.1038/leu.2016.94
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.94
This article is cited by
-
Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response
BMC Cancer (2022)
-
Deep molecular response in chronic myeloid leukemia
Leukemia (2016)
-
Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators
Leukemia (2016)